Yaşlılarda hipertansiyona yaklaşım

Çağlar Alp; Taner Sarak; Aydın Çifçi; Mehmet Kabalcı

doi:10.18663/tjcl.303497

Review

Approach to hypertension in the elderly

Year 2018, Volume: 9 Issue: 3, 233 - 236, 30.09.2018

Çağlar Alp Taner Sarak Aydın Çifçi Mehmet Kabalcı

https://doi.org/10.18663/tjcl.303497

Abstract

Hypertension is one
of the most important diseases of our age and an important cardiovascular risk
factor. The
average life span in the whole world is prolonged, and as a result, the elderly
population is increasing. Advanced age is associated with increased
hypertension prevalence. The prevalence of hypertension in Turkey is reaching 75%
over 65 years old.; There are some differences hypertension in the elderly from
other age groups in terms of etiopathogenesis, diagnosis and treatment.

Keywords

Hypertension, elderly, etiopathogenesis, treatment

References

1. Danon-Hersch N, Marques-Vidal P, Bovet P et al. Prevalence, awareness, treatment and control of high blood pressure in a Swiss city general population: the CoLaus study. Eur J Cardiovasc Prev Rehabil 2009; 16: 66-72.
2. Altun B, Arici G, Nergizoglu U et al. Renal, Prevalence, awareness, treatment and control of hypertension in Turkey (the PatenT study) in 2003. J Hypertens 2005; 23: 1817-23.
3. Aytekin T, Pala K, Irgil E, Akis N, Aytekin H. Distribution of blood pressures in Gemlik District, north-west Turkey. Health Soc Care Community, 2002; 10: 394-401.
4. Efstratopoulos AD, Voyaki SM, Baltas AA et al. Prevalence, awareness, treatment and control of hypertension in Hellas, Greece: the Hypertension Study in General Practice in Hellas (HYPERTENSHELL) national study. Am J Hypertens, 2006; 19: 53-60.
5. Millar-Craig M, Bishop C, Raftery E. Circadian variation of blood-pressure. The Lancet 1978; 311: 795-97.
6. Chobanian AV, Bakris GL, Black HR et al. Treatment of High Blood Pressure. National Heart, I. Blood, and C. National High Blood Pressure Education Program Coordinating, Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-52.
7. Weber MA, Schirin EL, White W et al. Clinical practice guidelines for the management of hypertension in the community a statement by the american society of hypertension and the international society of hypertension. J Hypertens. 2014; 32: 3-15.
8. Lakatta EG, Wang M, Najjar SS. Arterial aging and 12. subclinical arterial disease are fundamentally intertwined at macroscopic and molecular levels. Med Clin North Am 2009; 93: 583-604.
9. Pearce JD, Craven BL, Craven TE, Piercy KT, Stafford JM, Edwards MS, Hans en KJ. Progression of atherosclerotic renovascular disease: A prospective populationbased study. J Vasc Surg 2006; 44: 955–62
10. Zanchetti A, Grassi G, Mancia G. When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical re-appraisal. J Hypertens 2009; 27: 923–34 11. JATOS Study Group. Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS). Hypertens Res 2008; 31: 2115–27.
12. Wang JG, Staessen JA, Franklin SS et al. Systolic and diastolic blood pressure lowering as determinants of cardiovascular outcome. Hypertension 2005; 45: 907-13.
13. Mancia G, De Backer G, Dominiczak A et al. The 7. task force for the management of arterial hypertension of the European Society of H, The task force for the management of arterial hypertension of the European Society of C: 2007 guidelines for the management of arterial hypertension. The task force for the management of arterial hypertension of the european society of hypertension (esh) and of the european society of cardiology (esc). Eur Heart J 2007;28:1462-536